This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are a newer class of antidepressants that may have particular efficacy in Parkinson's disease (PD) given the known serotonergic alterations in this disease. These agents are also thought to have a favorable side-effect profile, particularly in the elderly. Several recent case reports, however, have raised concern that SSRIs may worsen parkinsonian motor function. We surveyed 71 Parkinson Study Group(PSG) investigators using a standardized questionnaire about their usage of antidepressants in PD. Based on estimates provided by 49 investigators (70%)(caring for approximately 23,410 PD patients) who responded, 26% of patients with PD are on pharmacotherapy for depression. These physicians use SSRIs as first line therapy 51% of the time, tricyclic antidepressants 41% of the time and other agents 8% of the time. The most common reasons for selecting SSRIs were their better side-effect profile and perceived greater efficacy. The most common reasons for selecting tricyclic antidepressants were their potential to help with sleep and the physician's experience with this class. Forty-three percent of investigators were concerned that SSRIs might worsen motor function, and 37% of them have had at least one patient in whom they believe this had occurred. Our survey confirms that for treating physicians there remain uncertainties regarding the relative efficacy and tolerability of available antidepressant medications for patients with PD. A controlled clinical trial of antidepressant therapy in PD would be valuable for settling these concerns.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.